Pfizer will end development on its experimental Duchenne muscular dystrophy gene therapy after a Phase 3 failure last month, and plans to eliminate roles at a North Carolina site that was working on the project.
The cuts affect about 150 workers involved in the Duchenne program and “other site operations” at Pfizer’s Sanford, NC facility, a company spokesperson confirmed to Endpoints News on Monday.
When the company announced the Phase 3 readout in June, it said it was still evaluating the future of the gene therapy, dubbed fordadistrogene movaparvovec.
In addition to the Sanford site cuts, Pfizer is also letting go 60 employees at its Rocky Mount, NC facility, a large sterile injectables site that was hit by a tornado last July. The company quickly restarted production after national attention and collaboration with the FDA. Some Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
